Cullinan Therapeutics Stock (NASDAQ:CGEM)

Forecast Ownership Financials Chart

Previous Close

$17.28

52W Range

$5.68 - $19.43

50D Avg

$16.12

200D Avg

$12.80

Market Cap

$1.05B

Avg Vol (3M)

$1.05M

Beta

-0.01

Div Yield

CGEM Company Profile

Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

109

IPO Date

Jan 08, 2021

Website

CGEM Performance

CGEM Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-241.65M	$-196.92M	$-191.09M
Net Income	$-219.88M	$-167.38M	$-153.16M
EBITDA	$-241.65M	$-167.15M	$-190.34M
Basic EPS	-	$-3.11	$-3.69
Diluted EPS	-	$-3.11	$-3.69

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
SY	So-Young International Inc.
CBLL	CeriBell, Inc.
BCYC	Bicycle Therapeutics plc
ADCT	ADC Therapeutics S.A.
OMER	Omeros Corporation
NMRA	Neumora Therapeutics, Inc. Common Stock
RAPT	RAPT Therapeutics, Inc.
LAB	Standard BioTools Inc.
VREX	Varex Imaging Corporation